The present invention relates to the use of a compound of formula I in the manufacture of a medicament for the treatment of schizophrenia, compulsive personality disorder, depression, bipolar disorder, anxiety disorder, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, Chronic schizophrenia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington ' s disease, stroke, and radiation therapy disorders, chronic (chronic) A compound of formula (I), or a pharmaceutically acceptable acid addition salt thereof, for treating the abuse of a neuro-active drug selected from alcohol, opioid, methamphetamine, phencyclidine and cocaine, Salts, racemic mixtures or the corresponding enantiomers and / or optical isomers thereof: (I) In this formula, R ' is hydrogen or lower alkyl； R <； 1 >； is halogen, lower alkyl, cycloalkyl or cyano, Lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, halogen, cyano, hydroxy, C (O) -NH- lower alkyl, CH 2 -C (O) -NH- lower alkyl 1 to 3 substituents selected from CH 2 -NH-C (O) -lower alkyl, CH 2 NH 2 , S (O) 2 CH 3 and S (O) 2 N (CH 3 ) 2 , or heterocycloalkyl Lt； / RTI >； is phenyl optionally substituted by one or more <； RTI ID = 4 <； / RTI >； or 5-yl optionally substituted by lower alkyl, Thiazol-5-yl optionally substituted by one or two lower alkyl groups, 2, 3 or 4-yl optionally substituted by lower alkyl, lower alkoxy, halogen or N (CH 3 ) 2 , 3,6-dihydro-2H-pyran, Benzo [d] [1,3] dioxol-5-yl, 2,3-dihydrobenzo [b] [1,4] dioxin-6-yl； R <； 2 >； is hydrogen, lower alkyl, or lower alkyl substituted by alkoxy, R 3 is hydrogen, lower alkyl, lower alkyl, NH-S (O) substituted with lower alkyl, hydroxy-substituted with halogen 2 -CH 3, - (CH 2 ) m -O- lower alkyl or - (CH 2 ) n -S (O) or 2 -CH 3, -S (O) 2 CH 3 optionally substituted by lower alkoxy or - (CR 2)n - or phenyl, Optionally substituted by lower alkyl and = O - (CH 2) n - , or hetero
